Distinctive patterns of Her-2/neu, c-myc, and cyclin D1 gene amplification by fluorescence in situ hybridization in primary human breast cancers.

BACKGROUND Human solid tumors undergo clonal evolution as they progress, but evidence for specific sequences of genetic changes that occur in individual tumors and are recapitulated in other tumors is difficult to obtain. METHODS Patterns of amplification of Her-2/neu, c-myc, and cyclin D1 were determined by fluorescence in situ hybridization (FISH) in relation to the presence of p53 dysfunction and ploidy in 60 primary human breast cancers. RESULTS We show that there are clusters of genophenotypic abnormalities that distinguish lobular breast cancers from nonlobular tumors; that cyclin D1 amplification occurs prior to the divergence of lobular breast cancers from nonlobular cancers; that p53 dysfunction, Her-2/neu amplification, and c-myc amplification are characteristic features of nonlobular breast cancers, but not of lobular breast cancers; and that the frequencies of amplification of all three oncogenes examined increase progressively with increasing aneuploidy, but that each gene exhibits a different profile of increasing amplification in relation to tumor progression. Early amplification of c-myc appears to be an especially prominent feature of hypertetraploid/hypertetrasomic tumors. CONCLUSIONS The data suggest that in tumors containing multiple abnormalities, these abnormalities often accumulate in the same cells within each tumor. Furthermore, the same patterns of accumulation of multiple genophenotypic abnormalities are recapitulated in different tumors.

[1]  K. Leslie,et al.  Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma. , 1990, Archives of pathology & laboratory medicine.

[2]  J F Silverman,et al.  Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  R. Hruban,et al.  Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. , 2000, Cancer research.

[4]  D. Horsfall,et al.  Relationship between ploidy and steroid hormone receptors in primary invasive breast cancer. , 1986, British Journal of Cancer.

[5]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[6]  G. Riou,et al.  Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. , 1988, Oncogene research.

[7]  T. Kiyono,et al.  The G2 Checkpoint Is Maintained by Redundant Pathways , 1999, Molecular and Cellular Biology.

[8]  A. Wyllie,et al.  Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. , 1995, British Journal of Cancer.

[9]  Patrick E Carroll,et al.  Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression , 1999, Oncogene.

[10]  T. Ried,et al.  Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability , 1998, Oncogene.

[11]  G. Woude,et al.  Abnormal Centrosome Amplification in the Absence of p53 , 1996, Science.

[12]  S. Hellman,et al.  Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. , 2000, Cancer research.

[13]  R. Zeillinger,et al.  Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. , 1997, Cancer research.

[14]  R. Hartsock,et al.  Sequential paraformaldehyde and methanol fixation for simultaneous flow cytometric analysis of DNA, cell surface proteins, and intracellular proteins. , 1992, Cytometry.

[15]  D. Slamon,et al.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.

[16]  Carissa A. Sanchez,et al.  Evolution of neoplastic cell lineages in Barrett oesophagus , 1999, Nature Genetics.

[17]  G. Wahl,et al.  Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles , 1992, Cell.

[18]  Carissa A. Sanchez,et al.  A p53-dependent mouse spindle checkpoint , 1995, Science.

[19]  E Gabrielson,et al.  Genetic divergence in the clonal evolution of breast cancer. , 1996, Cancer research.

[20]  P. Gariglio,et al.  In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. , 1988, Journal of the National Cancer Institute.

[21]  Carissa A. Sanchez,et al.  17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. , 1994, Cancer research.

[22]  J. Bartek,et al.  Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro , 1990, International journal of cancer.

[23]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[24]  R. Lidereau,et al.  Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Benchimol,et al.  The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. , 1993, The EMBO journal.

[26]  L. Medeiros,et al.  Differential expression of cyclin D1 in breast papillary carcinomas and benign papillomas: an immunohistochemical study. , 1999, Archives of pathology & laboratory medicine.

[27]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[28]  L. Strong,et al.  Spontaneous abnormalities in normal fibroblasts from patients with Li-Fraumeni cancer syndrome: aneuploidy and immortalization. , 1990, Cancer research.

[29]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[30]  A. C. Carter,et al.  Steroid hormone receptor immunohistochemistry and amplification of c‐myc protooncogene relationship to disease‐free survival in breast cancer , 1993, Cancer.

[31]  J. Nesland,et al.  Significant difference in p53 and p21 protein immunoreactivity in HPV 16 positive and HPV negative breast carcinomas. , 1999, Acta oncologica.

[32]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[33]  D. Lane,et al.  The p53 tumour suppressor gene , 1998, The British journal of surgery.

[34]  Persons Dl,et al.  Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization , 1997 .

[35]  P. Carroll,et al.  Genetic alterations in primary bladder cancers and their metastases. , 1998, Cancer research.

[36]  D. Horsfall,et al.  The significance of oncogene amplification in primary breast cancer , 1989, International journal of cancer.

[37]  C. Paraskeva,et al.  Mutant p53 is not fully dominant over endogenous wild type p53 in a colorectal adenoma cell line as demonstrated by induction of MDM2 protein and retention of a p53 dependent G1 arrest after gamma irradiation. , 1995, Oncogene.

[38]  S. Shackney,et al.  Model for the genetic evolution of human solid tumors. , 1989, Cancer research.

[39]  L. Norton,et al.  p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  P. V. van Diest,et al.  Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. , 1997, The American journal of pathology.

[41]  E. Prochownik,et al.  C-myc overexpression and p53 loss cooperate to promote genomic instability , 1999, Oncogene.

[42]  W. J. Brammar,et al.  Oncogene organisation and expression: prediction in breast cancer. , 1989, Hormone research.

[43]  D. Horsfall,et al.  Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  W. J. Brammar,et al.  Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. , 1991, Oncogene.

[45]  K. Kinzler,et al.  Genetic instability in colorectal cancers , 1997, Nature.

[46]  G. Stark,et al.  MYC Abrogates p53-Mediated Cell Cycle Arrest in N-(Phosphonacetyl)-l-Aspartate-Treated Cells, Permitting CAD Gene Amplification , 1998, Molecular and Cellular Biology.

[47]  I. Ellis,et al.  p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor. , 1992, British Journal of Cancer.

[48]  A. Feinberg,et al.  Microallelotyping defines the sequence and tempo of alleiic losses at tumour suppressor gene loci during colorectal cancer progression , 1995, Nature Medicine.

[49]  X. Chen,et al.  p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. , 1996, Genes & development.

[50]  R. Hartsock,et al.  Discrepancies between flow cytometric and cytogenetic studies in the detection of aneuploidy in human solid tumors. , 1990, Cytometry.

[51]  D. Carney,et al.  Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. , 1995, British Journal of Cancer.

[52]  Rochelle L. Garcia,et al.  C‐ERBB‐2 oncogens protein in In situ and invasive lobular breast neoplasia , 1991 .

[53]  Jiri Bartek,et al.  Cyclin D1 protein expression and function in human breast cancer , 1994, International journal of cancer.

[54]  C. Purdie,et al.  Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. , 1993, Oncogene.

[55]  E. Schröck,et al.  Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: A phenotype/genotype correlation , 1999, Genes, chromosomes & cancer.

[56]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[57]  D. Persons,et al.  Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[58]  T. Shankey,et al.  Common patterns of genetic evolution in human solid tumors. , 1997, Cytometry.

[59]  D. Pinkel,et al.  ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[60]  J. Cunningham,et al.  p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. , 1995, Oncogene.

[61]  S. Shackney,et al.  Karyotypic evolution of a human undifferentiated large cell carcinoma of the lung in tissue culture. , 1989, Cancer research.

[62]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[63]  Carissa A. Sanchez,et al.  17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[64]  T. Oyama,et al.  Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. , 1998, Cancer research.

[65]  A. Levine,et al.  Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.